Comparative Real-world Study on Ablative Fractional CO₂ Laser vs PRP With Microneedling for Acne Scar Treatment.
NCT ID: NCT07189923
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
116 participants
INTERVENTIONAL
2025-12-01
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fractional CO2 Laser Delivery of Topical Insulin Versus Platelet Rich Plasma in Treatment of Atrophic Post Acne Scars
NCT06590909
Combined Procedures in the Treatment of Severe Acne Scars
NCT06227481
Simultaneous Versus Sequential Fractional CO2 Laser and Subcision Combination for Post-acne Atrophic Scars: A Split-face Comparative Study.
NCT05688202
Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars
NCT06978361
Treatment of Acne Scars With Fractional CO2 Laser Versus Radio-frequency Microneedling
NCT04252352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Acne scars, notably atrophic scars, pose significant cosmetic and psychological concerns. Standard treatments include fractional lasers and microneedling-based interventions; however, rigorous comparative data in real-world clinical settings remain scarce. Recent evidence suggests ablative fractional CO2 laser and PRP-enhanced microneedling offer notable benefits. This split-face design allows direct comparison of efficacy, safety, and patient satisfaction between the modalities among Bangladeshi patients.
Study Design:
Type: Phase 3, open-label, randomized, split-face, comparative clinical trial
Planned Sample Size: 116 participants
Setting: Department of Dermatology, Dhaka Medical College Hospital, Bangladesh
Duration: April 2025 to March 2026
Randomization: Side of face assigned to either intervention via coin toss
Blinding: Open-label; outcome assessment by independent dermatologist blinded to intervention side
Eligibility Criteria:
Inclusion:
Age \>18 years
Both sexes
Grade 2-4 acne scarring (Goodman \& Baron qualitative grading)
Equal baseline scar grades on both facial halves
Atrophic scars only (no active acne)
Exclusion:
History of keloidal tendency
Bleeding or platelet disorders
Major surgery in past 6 months
Active facial infection (e.g., herpes, folliculitis)
HIV, hepatitis B surface antigen (HBsAg), or chronic illness
Pregnancy
Interventions:
Ablative Fractional CO2 Laser:
Pre-treatment: 2.5% lidocaine + 2.5% prilocaine cream (45 minutes), antiseptic cleansing
Device: SmartXide DOT Fractionated CO2 Laser (15 W, 800 μm spacing, 600 µs dwell, stack 2)
Three sessions, one month apart
PRP with Microneedling:
Pre-treatment: 2.5% lidocaine + 2.5% prilocaine cream (2 hours), antiseptic cleansing
PRP Preparation: 8 mL blood with double spin centrifugation to yield 2 mL PRP, platelet count verified
Intradermal PRP injection (nappage technique), followed by dermapen microneedling (1.5 mm depth, 12-needle cartridge, 4-directional passes)
Three sessions, one month apart
Follow-up and Data Collection:
Baseline, day 30, day 60, final (day 90 post first session)
Outcome measures collected via clinical assessments, standardized photographs, patient questionnaires, and independent dermatologist review
Adverse events monitored throughout
Outcome Measures:
Primary:
Change in Goodman \& Baron quantitative and qualitative acne scar grades at 90 days
Secondary:
Independent dermatologist evaluation (10-point VAS, categorized for analysis)
Patient satisfaction (5-point Likert scale)
Frequency and type of adverse events/side effects
Subgroup analyses by scar severity, skin type, and sex
Statistical Analysis:
All analyses by intention-to-treat
Continuous data: Paired t-tests (within-group), independent t-test or Mann-Whitney U (between modalities)
Qualitative grades: McNemar's test (within-group), chi-square (between modalities)
Categorical responses (dermatologist VAS, satisfaction, side effects): chi-square or Fisher exact
95% confidence intervals, significance level 0.05
Safety Monitoring:
Data and Safety Monitoring Board (DSMB) of independent experts
GCP compliance and interim reviews
Adverse event reporting follows national and institutional guidelines
Ethical Considerations:
Written informed consent (Bengali/English)
Withdrawal permitted at any time without detriment to care
Confidential data handling in accordance with local regulations
Institutional ethics committee approval obtained
Keywords:
Acne scars, fractional CO2 laser, platelet-rich plasma, microneedling, randomized trial, Bangladesh, split-face, dermatology, Goodman and Baron, patient satisfaction, safety
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ablative fractional CO2 laser
Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters include 15 W power, 800 µm spacing, 600 µs dwell time, and stack level 2. A total of three sessions will be administered, each one month apart.
Ablative Fractional CO₂ Laser
Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters: 15 W power, 800 µm spacing, 600 µs dwell time, stack level 2. Sessions: 3, each one month apart.
Platelet-Rich Plasma (PRP) With Microneedling
Participants will receive intradermal injections of autologous PRP followed by microneedling on the opposite side of the face. PRP will be prepared using a double-spin centrifugation method from 8 mL of venous blood. Microneedling will be performed with a Dermapen (12-needle cartridge, 1.5 mm depth) until pinpoint bleeding is observed. A total of three sessions will be administered, each one month apart.
Platelet-Rich Plasma (PRP) With Microneedling
Participants will receive intradermal autologous PRP injections prepared by double-spin centrifugation from 8 mL of venous blood, followed by microneedling with a Dermapen (12-needle cartridge, 1.5 mm depth). Endpoint: pinpoint bleeding. Sessions: 3, each one month apart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ablative Fractional CO₂ Laser
Participants will receive ablative fractional CO₂ laser therapy on one side of the face using the SmartXide DOT Fractionated CO₂ Laser system. Treatment parameters: 15 W power, 800 µm spacing, 600 µs dwell time, stack level 2. Sessions: 3, each one month apart.
Platelet-Rich Plasma (PRP) With Microneedling
Participants will receive intradermal autologous PRP injections prepared by double-spin centrifugation from 8 mL of venous blood, followed by microneedling with a Dermapen (12-needle cartridge, 1.5 mm depth). Endpoint: pinpoint bleeding. Sessions: 3, each one month apart.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both male and female sex
* Patients with grade 2 to grade 4 acne scars, classified on the basis of Goodman's Qualitative classification.
* Patient with equal Goodman's Qualitative scores on both halves of the face.
* No active acne lesions.
* Patients with atrophic scars only.
Exclusion Criteria
* Positive history of bleeding or platelet disorder.
* Positive history of major surgery in past 6 months.
* Presence of any acute infection on face like, herpes, folliculitis.
* Patients of HIV, HBsAg, or any chronic illness.
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dhaka Medical College
OTHER
Dr. Sirajul Islam Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Azmiree Binte Aslam
Assistant Professor, Department of Dermatology and Venereology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dhala Medical College
Dhaka, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-DMC/2025/48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.